Compare · GOSS vs PALI
GOSS vs PALI
Side-by-side comparison of Gossamer Bio Inc. (GOSS) and Palisade Bio Inc. (PALI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GOSS focuses on Biotechnology: Pharmaceutical Preparations, while PALI focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- PALI is the larger of the two at $342.0M, about 4.1x GOSS ($83.2M).
- Over the past year, GOSS is down 90.3% and PALI is up 108.1% - PALI leads by 198.4 points.
- PALI has been more active in the news (8 items in the past 4 weeks vs 4 for GOSS).
- GOSS has more recent analyst coverage (25 ratings vs 7 for PALI).
- Company
- Gossamer Bio Inc.
- Palisade Bio Inc.
- Price
- $0.17-0.58%
- $1.96+4.81%
- Market cap
- $83.2M
- $342.0M
- 1M return
- +1.67%
- +9.50%
- 1Y return
- -90.31%
- +108.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 7
Gossamer Bio Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Palisade Bio Inc.
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
Latest GOSS
- Gossamer Bio Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Gossamer Bio Inc.
- Gossamer Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
- Gossamer Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- SEC Form SCHEDULE 13D filed by Gossamer Bio Inc.
- SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.
- SEC Form DEF 14A filed by Gossamer Bio Inc.
- SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.
Latest PALI
- Director Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)
- Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
- Director Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)
- Chief Medical Officer Jones Mitchell Lawrence converted options into 131,167 shares and sold $106,536 worth of shares (51,880 units at $2.05), increasing direct ownership by 539% to 94,009 units (SEC Form 4) to satisfy tax liability
- CEO, CFO Finley John David exercised 335,300 shares at a strike of $0.00 and sold $303,343 worth of shares (146,798 units at $2.07), increasing direct ownership by 646% to 217,688 units (SEC Form 4) to cover withholding tax
- SEC Form 144 filed by Palisade Bio Inc.
- Director Baltera Robert Jr. bought $59,400 worth of shares (30,000 units at $1.98), increasing direct ownership by 9% to 366,904 units (SEC Form 4)
- Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
- Director Baltera Robert Jr. was granted 336,904 shares (SEC Form 4)
- SEC Form 3 filed by new insider Baltera Robert Jr.